Camp4 Therapeutics reported revenue of $1.78M and net income of -$33.53M for the quarter ended Jun 2026, up 18.8% year over year. This income statement covers 12 quarters of results from Sep 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.40M | 0.46M | 0.48M | 0.49M | 0.56M | 4.69M | 20.16M | 20.16M | 27.27M | 30.38M | 51.93M | 51.93M |
| Revenue & cost | ||||||||||||
| Revenue | 0.35M | 0.65M | 0.86M | 1.50M | 0.80M | 0.35M | 1.29M | 1.78M | ||||
| Operating items | ||||||||||||
| Research & DevelopmentR&D | 9.82M | 10.66M | 9.74M | 9.39M | 9.70M | 10.00M | 10.15M | 10.34M | 9.36M | 8.36M | 10.16M | 10.82M |
| Selling, General & AdministrativeSG&A | 2.87M | 2.81M | 3.13M | 3.27M | 3.81M | 4.69M | 3.81M | 4.18M | 4.60M | 4.77M | 4.21M | 4.34M |
| Other Operating ExpensesOther Opex | 0.49M | |||||||||||
| Operating ExpensesOpex | 12.69M | 13.48M | 12.88M | 12.66M | 13.52M | 14.69M | 13.96M | 14.53M | 14.45M | 13.12M | 14.37M | 15.16M |
| Operating IncomeOp. Inc | -12.34M | -13.48M | -12.88M | -12.66M | -13.52M | -14.03M | -13.10M | -13.03M | -13.65M | -12.78M | -13.07M | -13.38M |
| EBIT | -12.34M | -13.48M | -12.88M | -12.66M | -13.52M | -14.03M | -13.10M | -13.03M | -13.65M | -12.78M | -13.07M | -13.38M |
| Non-operating items | ||||||||||||
| Non Operating Interest Expenses | 0.05M | 0.08M | 0.06M | -0.14M | ||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.69M | 0.57M | 0.40M | 0.23M | 0.09M | 0.61M | 0.59M | 0.45M | 0.42M | 0.71M | 0.91M | 0.81M |
| Other Non Operating IncomeOther Non Op Inc. | 0.03M | -0.14M | -0.06M | 0.18M | 0.08M | -0.01M | -1.80M | -28.03M | -6.19M | -20.93M | ||
| Non Operating IncomeNon Op. Inc. | 0.64M | 0.49M | 0.42M | 0.09M | 0.03M | 0.76M | 0.67M | 0.44M | -1.45M | -27.51M | -5.26M | -20.15M |
| Net income details | ||||||||||||
| EBT | -11.70M | -12.99M | -12.48M | -12.43M | -13.48M | -13.28M | -12.51M | -12.57M | -13.23M | -12.07M | -12.16M | -12.57M |
| Profit After TaxPAT | -11.70M | -12.99M | -12.46M | -12.57M | -13.48M | -13.28M | -12.43M | -12.59M | -15.10M | -40.28M | -18.33M | -33.53M |
| Income from Continuing OperationsIncome (Continuing) | -11.70M | -12.99M | -12.48M | -12.43M | -13.48M | -13.28M | -12.51M | -12.57M | -13.23M | -12.07M | -12.16M | -12.57M |
| Consolidated Net IncomeConsol Net Inc. | -11.70M | -12.99M | -12.48M | -12.43M | -13.48M | -13.28M | -12.51M | -12.57M | -13.23M | -12.07M | -12.16M | -12.57M |
| Income towards Parent CompanyParent Net Inc | -11.70M | -12.99M | -12.48M | -12.43M | -13.48M | -13.28M | -12.51M | -12.57M | -13.23M | -12.07M | -12.16M | -12.57M |
| Net Income towards Common StockholdersNet Income | -11.70M | -12.99M | -12.48M | -12.43M | -13.48M | -13.28M | -12.51M | -12.57M | -13.23M | -12.07M | -12.16M | -12.57M |
| Additional items | ||||||||||||
| EPS (Basic) | -29.21 | -32.89 | -26.63 | -25.70 | -24.19 | -2.83 | -0.62 | -0.62 | -0.48 | -0.40 | -0.21 | -0.22 |
| EPS (Diluted) | -29.21 | -32.89 | -26.63 | -25.70 | -24.19 | -2.83 | -0.62 | -0.62 | -0.48 | -0.40 | -0.21 | -0.22 |
| Shares Outstanding | 0.40M | 0.39M | 0.47M | 0.48M | 0.56M | 4.69M | 20.15M | 20.16M | 27.27M | 30.38M | 57.92M | 57.93M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.40M | 0.39M | 0.47M | 0.48M | 0.56M | 4.69M | 20.15M | 20.16M | 27.27M | 30.38M | 57.92M | 57.93M |
| EBITDA | -12.34M | -13.48M | -12.88M | -12.66M | -13.52M | -14.03M | -13.10M | -13.03M | -13.65M | -12.78M | -13.07M | -13.38M |
| Interest ExpensesInt Expense | 0.05M | 0.08M | 0.06M | -0.14M |